Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)
about
Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International StudyThe clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.Residual Dyslipidemia Leads to Unfavorable Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary InterventionPrevalence and types of persistent dyslipidemia in patients treated with statins.A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study)A cluster-randomized controlled knowledge translation feasibility study in Alberta community pharmacies using the PARiHS framework: study protocol.Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009.Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.Correlates of Achieving Statin Therapy Goals in Children and Adolescents with DyslipidemiaCardiovascular risk factor modification among high-risk patients: Do pharmacists play a role?Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
P2860
Q30397875-1BA20189-37F5-40D5-9139-81AEB346EE52Q33630826-093C6679-20E7-442F-8ACC-1961A03A3378Q35843906-ED8D7378-D69E-4406-82C5-3228374FB003Q36530790-2BDCED1C-0CFD-4E7A-B2F3-1A33BA170519Q37141195-20CFCFFC-7A8C-42E1-9B50-24A91788FB0EQ37275370-8AE1539B-9E7F-4FD3-8371-E5708F1CB18EQ37343626-41303420-1BDD-492B-B758-F1C90883F188Q37700758-447F67AE-22D6-43A6-A880-19CB2B94E64CQ37972314-C88B3D69-C330-4E02-AC8C-CF430A8F1F2FQ38124404-4E82729B-0632-4F12-90E7-FF24E7E0E1A0Q38775598-1A2C0C82-2FEA-4E0D-AAB0-9FDD7BB4E822Q39425155-06633FA2-358F-48FA-9439-74CC89CC1830Q42150685-C333E48B-6D78-4FB3-B823-E6AF6FE22E00Q43484384-48DEF49C-A289-42B4-8449-37099598408F
P2860
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@ast
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@en
Prevalence of dyslipidemia in ...... Slipidemia International Study
@nl
type
label
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@ast
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@en
Prevalence of dyslipidemia in ...... Slipidemia International Study
@nl
prefLabel
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@ast
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@en
Prevalence of dyslipidemia in ...... Slipidemia International Study
@nl
P2093
P2860
P1476
Prevalence of dyslipidemia in ...... ia International Study (DYSIS)
@en
P2093
Anatoly Langer
DYSIS Canadian Investigators
Gordon A Francis
Lawrence A Leiter
Natacha R Bastien
Ruth McPherson
Shaun G Goodman
P2860
P304
P356
10.1016/S0828-282X(10)70454-2
P577
2010-11-01T00:00:00Z